Genome-wide CRISPR screens identify GATA6 as a proviral host factor for SARS-CoV-2 via modulation of ACE2

Ma’ayan Israeli, Yaara Finkel, Yfat Yahalom-Ronen, Nir Paran, Theodor Chitlaru, Ofir Israeli, Inbar Cohen-Gihon, Moshe Aftalion, Reut Falach, Shahar Rotem, Uri Elia, Ital Nemet, Limor Kliker, Michal Mandelboim, Adi Beth-Din, Tomer Israely, Ofer Cohen, Noam Stern-Ginossar, Adi Bercovich-Kinori

Research output: Contribution to journalArticlepeer-review

15 Scopus citations


The global spread of SARS-CoV-2 led to major economic and health challenges worldwide. Revealing host genes essential for infection by multiple variants of SARS-CoV-2 can provide insights into the virus pathogenesis, and facilitate the development of novel therapeutics. Here, employing a genome-scale CRISPR screen, we provide a comprehensive data-set of cellular factors that are exploited by wild type SARS-CoV-2 as well as two additional recently emerged variants of concerns (VOCs), Alpha and Beta. We identified several host factors critical for SARS-CoV-2 infection, including various components belonging to the Clathrin-dependent transport pathway, ubiquitination, Heparan sulfate biogenesis and host phosphatidylglycerol biosynthesis. Comparative analysis of the different VOCs revealed the host factors KREMEN2 and SETDB1 as potential unique candidates required only to the Alpha variant. Furthermore, the analysis identified GATA6, a zinc finger transcription factor, as an essential proviral gene for all variants inspected. We show that GATA6 directly regulates ACE2 transcription and accordingly, is critical for SARS-CoV-2 cell entry. Analysis of clinical samples collected from SARS-CoV-2 infected individuals shows elevated levels of GATA6, suggesting a role in COVID-19 pathogenesis. Finally, pharmacological inhibition of GATA6 resulted in down-modulation of ACE2 and inhibition of viral infectivity. Overall, we show GATA6 may represent a target for the development of anti-SARS-CoV-2 therapeutic strategies and reaffirm the value of the CRISPR loss-of-function screens in providing a list of potential new targets for therapeutic interventions.

Original languageEnglish
Article number2237
JournalNature Communications
Issue number1
StatePublished - Dec 2022
Externally publishedYes

Bibliographical note

Funding Information:
We thank Emanuelle Mamroud for providing valuable feedback; Tamar Aminov and Inbar Chomsky for technical assistance; and Shay Weiss for biosafety guidance.

Publisher Copyright:
© 2022, The Author(s).


Dive into the research topics of 'Genome-wide CRISPR screens identify GATA6 as a proviral host factor for SARS-CoV-2 via modulation of ACE2'. Together they form a unique fingerprint.

Cite this